Inferra AI / Company / CNS
Cohen & Steers, Inc.
CNS · Financials
Last earnings Oct 15, 2026
Key results
Operating marginquarter
28.0%
Operating margin of 28.0% 36.4% as adjusted Ending AUM of $90.5 billion average AUM of $90.8 billion Net inflows of $1.2 billion
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
EPSquarter
$2.97
Diluted EPS of $2.97 $3.09 as adjusted
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Operating margin of 32.0% 35.2% as adjusted Average AUM of $88.6 billion Net inflows of $1.5 billion
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Operating Margin Operating margin was 28.0% for the fourth quarter of 2025, compared with 34.5% for the third quarter of 2025, primarily due to expenses associated with the UTF rights offering of $10.8 million.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
GAAP $ 40,310 $ 48,901 $ 49,337 $ 177,736 $ 172,877 Fund related amounts (1) 1,315 184 280 2,058 1,551 Accelerated vesting of restricted stock units (77) 1,142 91 3,269 7,134 Lease transition and other costs - 280 Park Avenue (2) 807 Fund launch and rights offering costs 10,814 650 11,464 Other non-recurring expenses (3) 616 1,196 Operating income, as adjusted $ 52,362 $ 50,877 $ 49,708 $ 195,143 $ 183,565 Operating margin, U.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
GAAP 28.0 % 34.5 % 35.3 % 32.0 % 33.4 % Operating margin, as adjusted 36.4 % 36.1 % 35.5 % 35.2 % 35.4 % __________________________ (1) Represents the impact of consolidated funds and expenses incurred on behalf of certain company-sponsored funds.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Operating incomequarter
$40,310 thousand
Operating income 40,310 48,901 49,337 (17.6 %) (18.3 %
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Net incomequarter
$34,879 thousand
Net income attributable to common stockholders $ 34,879 $ 41,711 $ 45,822 (16.4 %) (23.9 %
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
AI analysis
Q3 2025 · reported Jan 22, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q3 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Operating margin | 28.0% | — | — |
| EPS | $2.97 | — | — |
| Operating income | $40,310 thousand | — | — |
| Net income | $34,879 thousand | — | — |
Guidance · company-stated
No guidance located in the held release
Margin
Capital allocation
Supplemental disclosures of non-cash investing and financing activities: In connection with its stock incentive plan, the Company issued dividend equivalents in the form of restricted stock units, net of forfeitures, in the amount of $ 1.9 million and $ 1.4 million for the six months ended June 30, 2026 and 2025, respectively.
Treasury securities and investment-grade corporate debt securities.
Event summary
GAAP to as adjusted results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Supplemental disclosures of non-cash investing and financing activities: In connection with its stock incentive plan, the Company issued dividend equivalents in the form of restricted stock units, net of forfeitures, in the amount of $ 1.9 million and $ 1.4 million for the six months ended June 30, 2026 and 2025, respectively.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Treasury securities and investment-grade corporate debt securities.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
(the Amended Credit Agreement) providing for a $ 100.0 million senior unsecured revolving credit facility maturing on August 15, 2029.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Borrowings under the Amended Credit Agreement bear interest at a variable annual rate equal to, at the Company s option, either, (i) in respect of Term Secured Overnight Financing Rate (SOFR) Loans, a rate equal to Term SOFR in effect for such period plus an applicable rate as determined according to a performance pricing grid and, (ii) in respect of Base Rate Loans, a rate equal to a Base Rate plus an applicable rate as determined according to a performance pricing grid.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
The Company is also required to pay a commitment fee based on the actual daily unused amount of the credit facility payable quarterly.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Borrowings under the Amended Credit Agreement may be used for working capital and other general corporate purposes.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Strategy & priorities
real estate, $89 million into real assets multi-strategy (included in Other ) and $59 million into global listed infrastructure, partially offset by net outflows of $358 million from preferred securities Market depreciation of $568 million from U.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
real estate, partially offset by net outflows of $134 million from real assets multi-strategy (included in Other ) and Market depreciation of $147 million from U.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Outperformance is determined by comparing the annualized investment performance of each investment strategy to the performance of specified reference benchmarks.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
The investment performance calculation of each investment strategy is based on all active accounts and investment models pursuing similar investment objectives.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
About Cohen Steers Cohen Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Risks & headwinds
Such forward-looking statements are subject to various risks and uncertainties.
SEC original ↗Cohen & Steers, Inc. — Earnings release (8-K exhibit)EX-99Jan 22, 2026
Legal Proceedings 35 Item 1A.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Macroeconomic Environment Global economic conditions remained volatile through the second quarter of 2026, with many of the uncertainties that characterized the first quarter continuing to influence markets.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Central banks continued to balance gradual progress on core inflation against signs of moderating employment growth and energy prices, and policy uncertainty remained a driver of market dynamics even as corporate fundamentals were generally upbeat.
SEC original ↗Cohen & Steers, Inc. — 10-Q Quarterly report10-QJul 31, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
40 documents- Q3 2026
- 8-KCNS
Oct 15, 2026
- EX-99CNS
Oct 15, 2026
- Q2 2026
- 10-QCNS
Jul 31, 2026
- 8-KCNS
Jul 16, 2026
- EX-99CNS
Jul 16, 2026
- Q1 2026
- 8-KCNS
May 21, 2026
- 8-KCNS
May 4, 2026
- 10-QCNS
May 1, 2026
- 8-KCNS
Apr 16, 2026
- EX-99CNS
Apr 16, 2026
- Q4 2025
- 10-KCNS
Feb 27, 2026
- 8-KCNS
Jan 22, 2026
- EX-99CNS
Jan 22, 2026
- Q3 2025
- 10-QCNS
Oct 31, 2025
- 8-KCNS
Oct 16, 2025
- EX-99CNS
Oct 16, 2025
- Q2 2025
- 8-KCNS
Sep 15, 2025
- 8-KCNS
Aug 15, 2025
- 10-QCNS
Aug 1, 2025
- 8-KCNS
Jul 17, 2025
- EX-99CNS
Jul 17, 2025
- Q1 2025
- 8-KCNS
May 5, 2025
- 10-QCNS
May 2, 2025
- 8-KCNS
Apr 16, 2025
- EX-99CNS
Apr 16, 2025
- Q4 2024
- 8-KCNS
Mar 10, 2025
- 10-KCNS
Feb 21, 2025
- 8-KCNS
Jan 22, 2025
- EX-99CNS
Jan 22, 2025
- Q3 2024
- 8-KCNS
Dec 17, 2024
- 8-KCNS
Nov 8, 2024
- 10-QCNS
Nov 8, 2024
- 8-KCNS
Oct 16, 2024
- EX-99CNS
Oct 16, 2024
- Q2 2024
- 8-KCNS
Aug 19, 2024
- 10-QCNS
Aug 2, 2024
- 8-KCNS
Jul 17, 2024
- EX-99CNS
Jul 17, 2024
- Q1 2024
- 8-KCNS
Jun 24, 2024
- 8-KCNS
Jun 21, 2024
Earnings releases
11 documentsPresentations
0 documentsNo presentations for Cohen & Steers, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Cohen & Steers, Inc. are held in this edition of the library.
Mentioned by
9 companiesOther tracked companies whose held documents mention Cohen & Steers, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
Supernus Pharmaceuticals, Inc. (SUPN)
“ion File No.: 001-35518 Date: August 3, 2026 Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale AUGUST 3, 2026… …macroeconomic and market conditions, including economic downturns, international conflict, ”
Indivior Pharmaceuticals, Inc. (INDV)
“ 2 d166865dex991.htm EX-99.1 EX-99.1 Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale AUGUST 3, 2026… …macroeconomic and market conditions, including economic downturns, international conflict, ”
“with the Securities… …measure, including in 6 subscales assessing central nervous system (CNS) disease manifestations (cognitive impairment, sleep disturbances, fatigue, communication, emotional issues and pain). In the pooled dose group at… …acceler”
Harmony Biosciences Holdings, Inc. (HRMY)
“velopment, acquisition/licensing, launch and commercialization of multiple broad and rare CNS therapies. Mr. Anastasiou also… … and step down as a member of the Board. The Company reiterates full-year 2026 WAKIX® net revenue guidance of $1.0 billio”
Oric Pharmaceuticals, Inc. (ORIC)
“entify, hire… …demonstrate that modestly improved systemic ORR and significantly improved CNS ORR are associated with dramatically longer progression-free survival in Phase 3 head-to-head trials Source: Soria et al. N Engl…”
Alnylam Pharmaceuticals (ALNY)
“ Non-GAAP Net loss… …Establishing First-Ever Human Translation of RNAi Therapeutics in CNS – − Reiterated 2023 Financial Guidance, Including Combined Net Product Revenues of $1,200 Million to $1,285 Million – CAMBRIDGE, Mass.--(BUSINESS…”
Axsome Therapeutics, Inc. (AXSM)
“2040s >150M Patients impacted 3Q 2025 performance Innovation Discipline… …expanding CNS portfolio EDS = Excessive daytime sleepiness; OSA = Obstructive sleep apnea Rx, sales, and revenue growth vs. comparable periods in 2024 ~$5B combined peak ”
“… Effective in reducing severity and frequency of VMS. ● Warnings for CNS depressant effect, daytime impairment, and liver enzyme elevation. Requires liver monitoring. Elinzanetant (LynkuetTM) by Bayer Differentiation… …statements”
“…in the clinic, they have been limited by CNS effects such as somnolence, speech disorder, and memory impairment. Demonstrating target engagement without affecting the power spectra of low frequency ban”
See also the earnings calendar for every tracked company’s next earnings date.